- Home
- NTIP vs IGC Comparison
NTIP vs IGC Comparison
Compare NTIP & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- IGC
- Stock Information
- Founded
- NTIP 1990
- IGC 2005
- Country
- NTIP United States
- IGC United States
- Employees
- NTIP N/A
- IGC N/A
- Industry
- NTIP Multi-Sector Companies
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- IGC Health Care
- Exchange
- NTIP Nasdaq
- IGC Nasdaq
- Market Cap
- NTIP 32.0M
- IGC 33.5M
- IPO Year
- NTIP 1998
- IGC N/A
- Fundamental
- Price
- NTIP $1.37
- IGC $0.38
- Analyst Decision
- NTIP
- IGC Strong Buy
- Analyst Count
- NTIP 0
- IGC 2
- Target Price
- NTIP N/A
- IGC $3.88
- AVG Volume (30 Days)
- NTIP 16.2K
- IGC 812.2K
- Earning Date
- NTIP 08-08-2025
- IGC 08-14-2025
- Dividend Yield
- NTIP 7.14%
- IGC N/A
- EPS Growth
- NTIP N/A
- IGC N/A
- EPS
- NTIP N/A
- IGC N/A
- Revenue
- NTIP $150,000.00
- IGC $1,327,000.00
- Revenue This Year
- NTIP N/A
- IGC $15.26
- Revenue Next Year
- NTIP N/A
- IGC $3.41
- P/E Ratio
- NTIP N/A
- IGC N/A
- Revenue Growth
- NTIP N/A
- IGC 24.95
- 52 Week Low
- NTIP $1.16
- IGC $0.25
- 52 Week High
- NTIP $1.78
- IGC $0.48
- Technical
- Relative Strength Index (RSI)
- NTIP 46.72
- IGC 60.78
- Support Level
- NTIP $1.39
- IGC $0.35
- Resistance Level
- NTIP $1.44
- IGC $0.37
- Average True Range (ATR)
- NTIP 0.03
- IGC 0.02
- MACD
- NTIP -0.01
- IGC 0.00
- Stochastic Oscillator
- NTIP 6.32
- IGC 91.09
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.